Balance Sheet StrengthLow leverage and a sizable equity base provide durable financial flexibility over the next several months. This structure reduces near-term bankruptcy risk, supports continued R&D funding or trial activity, and gives management optionality to time any financing or partnerships more strategically.

Improving Cash BurnA reduction in negative free cash flow signals operational progress and improved cost dynamics versus prior periods. Sustained lower burn can extend runway, reduce near-term external funding needs, and materially lower dilution risk if the trend continues through upcoming quarters.

Narrowing Losses / EPS TrendNarrowing losses and positive EPS growth metrics indicate progress toward improved profitability. Over a multi-month horizon, this trend supports credibility with investors and counterparties and can make future financing easier or cheaper if management sustains the underlying cost controls or revenue stabilization.

Bears Say

Revenue CollapseZero reported revenue removes operating cash inflows and shows the company lacks commercial scale today. Without recurring sales, the business must rely on clinical progress, licensing or financing to create durable cash generation, increasing execution and funding risk over the medium term.

Persistent Negative Cash FlowsOngoing negative operating and free cash flows force reliance on external funding to sustain operations. This structural dependency can lead to repeated dilution or restrictive financing terms, limiting strategic flexibility and increasing vulnerability to funding market cycles over the next several months.

Eroding Equity And AssetsA declining equity and asset base indicates the company is consuming its financial cushion. Continued erosion reduces the ability to absorb trial setbacks or fund pivots, raises leverage risk if new debt is taken, and heightens the urgency for profitable operations or fresh capital in the medium term.

IMMU FAQ

What was Immunicum AB’s price range in the past 12 months?

Immunicum AB lowest stock price was kr4.01 and its highest was kr10.98 in the past 12 months.

What is Immunicum AB’s market cap?

Immunicum AB’s market cap is kr254.12M.

When is Immunicum AB’s upcoming earnings report date?

Immunicum AB’s upcoming earnings report date is May 08, 2026 which is in 62 days.

How were Immunicum AB’s earnings last quarter?

Immunicum AB released its earnings results on Feb 11, 2026. The company reported -kr0.74 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.74.

Is Immunicum AB overvalued?

According to Wall Street analysts Immunicum AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immunicum AB pay dividends?

Immunicum AB does not currently pay dividends.

What is Immunicum AB’s EPS estimate?

Immunicum AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immunicum AB have?

Immunicum AB has 62,584,580 shares outstanding.

What happened to Immunicum AB’s price movement after its last earnings report?

Immunicum AB reported an EPS of -kr0.74 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.055%.

Which hedge fund is a major shareholder of Immunicum AB?

Currently, no hedge funds are holding shares in SE:IMMU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immunicum AB

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.